Combined Oral Contraceptives in Patients with Family History of LCIS
Yes, a patient with a family history of LCIS in two relatives can safely use combined oral contraceptives. The evidence shows that family history of breast cancer (including LCIS) does not significantly increase breast cancer risk with modern oral contraceptive formulations.
Key Reasoning
Family History Does Not Contraindicate COC Use
The most robust evidence demonstrates that oral contraceptive use does not significantly modify breast cancer risk among women with a family history of breast cancer 1. A systematic review of 10 studies plus a pooled analysis of 54 studies found no significant increase in breast cancer risk for women with familial history using OCs 1.
Important Caveats About Formulation Timing
- Pre-1975 formulations (high-dose estrogen/progestin) showed elevated risk in women with first-degree family history (RR 3.3) 2
- Modern formulations (post-1975, lower-dose) do not demonstrate this elevated risk 1, 2
- The Cancer and Steroid Hormone Study found no evidence that even long-term OC use contributed to breast cancer risk in women with first-degree family history 3
LCIS-Specific Context
LCIS itself is a marker of increased breast cancer risk (8-10 fold increased risk), not a direct precursor 4. However:
- The patient has only a family history of LCIS, not personal LCIS
- Family history of LCIS in relatives (not first-degree with breast cancer) represents lower risk than personal LCIS
- No evidence suggests that family history of LCIS specifically contraindicates COC use
Risk-Benefit Considerations
COCs provide protective benefits that may be particularly relevant 5, 6:
- Decreased risk of ovarian cancer (ongoing and prolonged use)
- Decreased risk of endometrial cancer
- Decreased risk of colorectal cancer
The breast cancer risk, if any, appears temporary and limited to current or recent users, with no consistent evidence of increased risk in modern formulations 5.
Clinical Pitfalls to Avoid
- Do not conflate personal LCIS with family history of LCIS - these carry different risk profiles
- Do not apply data from pre-1975 high-dose formulations to modern low-dose COCs
- Do not assume all family history carries equal risk - first-degree relatives with invasive breast cancer represent higher concern than relatives with LCIS
Practical Approach
Prescribe modern low-dose combined oral contraceptives without restriction in this patient, while counseling about:
- The protective benefits against ovarian, endometrial, and colorectal cancers
- The lack of evidence for increased breast cancer risk with family history and modern formulations
- Standard breast cancer screening recommendations based on family history